ABSTRACT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 RAs are common therapies for managing diabetes and obesity, but gastrointestinal (GI) adverse effects (AEs) such as nausea, vomiting, diarrhea, and constipation frequently limit therapy
A recent report highlights that Ozempic and other weight loss drugs, including Wegovy, have been linked to 162 deaths in the U.S
If you experience suicidal thoughts, severe depression, or significant mood disruption, contact your provider immediately, as FDA guidance recommends discontinuation for suicidal thoughts or behaviors
See results or get your money back
Eventually, some patients may taper off medication under medical guidance, while others continue long-term maintenance depending on individual progress
BTW, I have been on a GLP-1 for 6 years, and have never lost a pound, but my A1C is really good